RxDoctor Payments Data

Eric Hames, MD

Family Medicine · Fort Worth, TXNPI 1174917116

Payments from drug & device makers

$1,381in general payments, 2019–2025

Across 90 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$290
  • AstraZeneca$240
  • Lilly USA, LLC$176
  • Pfizer$147
  • Boehringer Ingelheim$102
  • GSK$98
  • plus $328 from 9 others

What the payments were for

  • Food & beverage$1,375100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,381 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$69,312
Medicare patients
221
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$195,303
TrulicityDulaglutide99$126,306
JardianceEmpagliflozin72$97,000
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$65,341
EliquisApixaban59$53,042
MounjaroTirzepatide28$39,848
FarxigaDapagliflozin Propanediol25$32,571
XareltoRivaroxaban22$26,480
JanuviaSitagliptin Phosphate15$19,543
Tresiba Flextouch U-200Insulin Degludec13$14,647
RayaldeeCalcifediol11$14,546
Breo ElliptaFluticasone/Vilanterol16$13,561
LinzessLinaclotide13$12,247
MyrbetriqMirabegron15$11,591
Tresiba Flextouch U-100Insulin Degludec21$8,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$290$195,303142 claims
Lilly USA, LLCTrulicity, Mounjaro$176$166,154127 claims
Boehringer IngelheimJardiance$102$97,00072 claims
GSKTrelegy Ellipta, Breo Ellipta$98$78,90263 claims
PfizerEliquis$147$53,04259 claims
AstraZenecaFarxiga, Symbicort$240$37,70946 claims
Johnson & JohnsonXarelto$24$26,48022 claims
MerckJanuvia, Belsomra$28$24,51326 claims
Astellas Pharma US IncMyrbetriq$55$11,59115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →